Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an anti-cancer active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the anti-cancer active pharmaceutical ingredient is selected from ibrutinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, and capecitabine.
| # | Name | Date |
|---|---|---|
| 1 | 202147006962-FORM 1 [19-02-2021(online)].pdf | 2021-02-19 |
| 1 | 202147006962-Response to office action [30-12-2022(online)].pdf | 2022-12-30 |
| 2 | 202147006962-DRAWINGS [19-02-2021(online)].pdf | 2021-02-19 |
| 2 | 202147006962-FER.pdf | 2022-06-20 |
| 3 | 202147006962-FORM 18 [10-05-2022(online)].pdf | 2022-05-10 |
| 3 | 202147006962-COMPLETE SPECIFICATION [19-02-2021(online)].pdf | 2021-02-19 |
| 4 | 202147006962.pdf | 2021-10-18 |
| 4 | 202147006962-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [19-02-2021(online)].pdf | 2021-02-19 |
| 5 | 202147006962-FORM 3 [16-04-2021(online)].pdf | 2021-04-16 |
| 5 | 202147006962-FORM 3 [23-02-2021(online)].pdf | 2021-02-23 |
| 6 | 202147006962-ENDORSEMENT BY INVENTORS [23-02-2021(online)].pdf | 2021-02-23 |
| 7 | 202147006962-FORM 3 [16-04-2021(online)].pdf | 2021-04-16 |
| 7 | 202147006962-FORM 3 [23-02-2021(online)].pdf | 2021-02-23 |
| 8 | 202147006962-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [19-02-2021(online)].pdf | 2021-02-19 |
| 8 | 202147006962.pdf | 2021-10-18 |
| 9 | 202147006962-COMPLETE SPECIFICATION [19-02-2021(online)].pdf | 2021-02-19 |
| 9 | 202147006962-FORM 18 [10-05-2022(online)].pdf | 2022-05-10 |
| 10 | 202147006962-FER.pdf | 2022-06-20 |
| 10 | 202147006962-DRAWINGS [19-02-2021(online)].pdf | 2021-02-19 |
| 11 | 202147006962-Response to office action [30-12-2022(online)].pdf | 2022-12-30 |
| 11 | 202147006962-FORM 1 [19-02-2021(online)].pdf | 2021-02-19 |
| 1 | searchstrategy202147006962E_17-06-2022.pdf |